Interview with CEO, Linda Persson, in Privata Affรคrer

๐ƒ๐จ ๐ฒ๐จ๐ฎ ๐ฐ๐š๐ง๐ญ ๐ญ๐จ ๐ค๐ง๐จ๐ฐ ๐ฆ๐จ๐ซ๐ž ๐š๐›๐จ๐ฎ๐ญ ๐๐š๐ง๐จ๐„๐œ๐ก๐จโ€™๐ฌ ๐ข๐ง๐ง๐จ๐ฏ๐š๐ญ๐ข๐ฏ๐ž ๐๐ข๐š๐ ๐ง๐จ๐ฌ๐ญ๐ข๐œ ๐ฆ๐ž๐ญ๐ก๐จ๐ ๐š๐ง๐ ๐ญ๐ก๐ž ๐จ๐ง๐ ๐จ๐ข๐ง๐  ๐ฌ๐ก๐š๐ซ๐ž ๐ข๐ฌ๐ฌ๐ฎ๐ž?

Don’t miss the interview with our CEO, Linda Persson, in Privata Affรคrer. NanoEcho is currently conducting a new share issue to enter the clinical phase with our patented diagnostic method, which aims to improve healthcare by providing patients with a more accurate diagnosis and personalised treatment.

โ€“ With our new patented technology, we aim to prevent unnecessary surgeries for patients, reducing their suffering while generating significant health-economic benefits, both within healthcare and in society as a whole, says Linda Persson, CEO of NanoEcho.

Read the full article: https://lnkd.in/dfZjkw56

Learn more about the ongoing share issue: https://lnkd.in/dH_uUs5h

NanoEchoโ€™s innovative method, with its high precision, aims to facilitate the differentiation between diseased and healthy tissue and at the same time determine a more precise localization of cancerous tissue. The goal is to provide a more reliable diagnosis of, for example cancer diseases, that has the potential to contribute to cost-effectiveness in the health care.

NanoEcho AB
Scheelevรคgen 19,
223 63 Lund
info@nanoecho.se

Facebook Linkedin Youtube Envelope
Copyright 2024 NanoEcho ยฉ All Rights Reserved.
Privacy policy

We use cookies to enhance your experience on our website and analyze our traffic. By clicking ‘Accept,’ you consent to our use of cookies. You can learn more about the types of cookies we use and how to manage them in our privacy policy.

Accept